Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
The deal includes upfront payments, milestone payments and ongoing royalties
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
The company received gross proceeds of approximately US$1.7 million and net proceeds,
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Marks remarkable acceleration in innovation using AI technology
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Subscribe To Our Newsletter & Stay Updated
